跳至主要内容
临床试验/NCT06612671
NCT06612671进行中(未招募)不适用

Prognostic Factors and Oncological Outcome Analysis of Retroperitoneal Sarcoma

Taichung Veterans General Hospital1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2023年10月1日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
150
试验地点
1
主要终点
Overall survival

研究概览

简要总结

Investigators tried condult a retrospective study to analysis the prognostic factors and oncological outcome analysis of Retroperitoneal Sarcoma treated in our high volume medical center.

详细描述

Retroperitoneal Sarcoma (RPS) which is a rare disease which incidence is 1.79/100,000. The treatment is difficult to due to it anatomy position which often invade to multiple organs and cause the complete surgical resection to be very complex and difficult. It was known to sacrifice one side kidney will improve the resection rate. To this days, successful surgical resection was still the gold standard that provide most benefit in overall survival. To reach that goal, pre-operative radiotherapy was applied to RPS which intended to achieve similar effect in rectal cancer for the down staging effect and improved the respectability but with limited benefit. Herein, investigators conducted this study to find the best way to achieve successful surgical resection and prognostic factor analysis.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Retrospective

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • the patient who have retroperitoneal maliganacy and receive complete tumor excision in our hospital

排除标准

  • the patient did not receive complete tumor excision in our hospital
  • the pathological report yielded not malignancy tumor

结局指标

主要结局

Overall survival

时间窗: The proportion of patients still alive at 1 year, 3 years, and 5 years after treatment.

After treatment, patients will undergo long-term follow-up to record their survival status.

次要结局

  • Progression free survival(The rates of local recurrence, regional recurrence, or distant metastasis at 1 year, 3 years, and 5 years after treatment.)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验